| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate) |
| Brand | Stribild® |
| Indication | For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®. |
| Assessment Process | |
| Rapid review commissioned | 28/04/2013 |
| Rapid review completed | 17/05/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
06/12/2013 Following commercial discussions with Gilead, the HSE has approved hospital pricing of Stribild®
